Cargando…

Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors

Diabetic kidney disease (DKD) is one of the most important comorbidities for patients with diabetes, and its incidence has exceeded one tenth, with an increasing trend. Studies have shown that diabetes is associated with a decrease in the number of podocytes. Diabetes can induce apoptosis of podocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiutian, Wang, Jiali, Lin, Yongda, Liu, Yiping, Zhou, Tianbiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736207/
https://www.ncbi.nlm.nih.gov/pubmed/36497173
http://dx.doi.org/10.3390/cells11233913
_version_ 1784846966361948160
author Chen, Xiutian
Wang, Jiali
Lin, Yongda
Liu, Yiping
Zhou, Tianbiao
author_facet Chen, Xiutian
Wang, Jiali
Lin, Yongda
Liu, Yiping
Zhou, Tianbiao
author_sort Chen, Xiutian
collection PubMed
description Diabetic kidney disease (DKD) is one of the most important comorbidities for patients with diabetes, and its incidence has exceeded one tenth, with an increasing trend. Studies have shown that diabetes is associated with a decrease in the number of podocytes. Diabetes can induce apoptosis of podocytes through several apoptotic pathways or induce autophagy of podocytes through related pathways. At the same time, hyperglycemia can also directly lead to apoptosis of podocytes, and the related inflammatory reactions are all harmful to podocytes. Podocyte damage is often accompanied by the production of proteinuria and the progression of DKD. As a new therapeutic agent for diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to be effective in the treatment of diabetes and the improvement of terminal outcomes in many rodent experiments and clinical studies. At the same time, SGLT2i can also play a protective role in diabetes-induced podocyte injury by improving the expression of nephrotic protein defects and inhibiting podocyte cytoskeletal remodeling. Some studies have also shown that SGLT2i can play a role in inhibiting the apoptosis and autophagy of cells. However, there is no relevant study that clearly indicates whether SGLT2i can also play a role in the above pathways in podocytes. This review mainly summarizes the damage to podocyte structure and function in DKD patients and related signaling pathways, as well as the possible protective mechanism of SGLT2i on podocyte function.
format Online
Article
Text
id pubmed-9736207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97362072022-12-11 Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors Chen, Xiutian Wang, Jiali Lin, Yongda Liu, Yiping Zhou, Tianbiao Cells Review Diabetic kidney disease (DKD) is one of the most important comorbidities for patients with diabetes, and its incidence has exceeded one tenth, with an increasing trend. Studies have shown that diabetes is associated with a decrease in the number of podocytes. Diabetes can induce apoptosis of podocytes through several apoptotic pathways or induce autophagy of podocytes through related pathways. At the same time, hyperglycemia can also directly lead to apoptosis of podocytes, and the related inflammatory reactions are all harmful to podocytes. Podocyte damage is often accompanied by the production of proteinuria and the progression of DKD. As a new therapeutic agent for diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to be effective in the treatment of diabetes and the improvement of terminal outcomes in many rodent experiments and clinical studies. At the same time, SGLT2i can also play a protective role in diabetes-induced podocyte injury by improving the expression of nephrotic protein defects and inhibiting podocyte cytoskeletal remodeling. Some studies have also shown that SGLT2i can play a role in inhibiting the apoptosis and autophagy of cells. However, there is no relevant study that clearly indicates whether SGLT2i can also play a role in the above pathways in podocytes. This review mainly summarizes the damage to podocyte structure and function in DKD patients and related signaling pathways, as well as the possible protective mechanism of SGLT2i on podocyte function. MDPI 2022-12-03 /pmc/articles/PMC9736207/ /pubmed/36497173 http://dx.doi.org/10.3390/cells11233913 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chen, Xiutian
Wang, Jiali
Lin, Yongda
Liu, Yiping
Zhou, Tianbiao
Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
title Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
title_full Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
title_fullStr Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
title_full_unstemmed Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
title_short Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
title_sort signaling pathways of podocyte injury in diabetic kidney disease and the effect of sodium-glucose cotransporter 2 inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736207/
https://www.ncbi.nlm.nih.gov/pubmed/36497173
http://dx.doi.org/10.3390/cells11233913
work_keys_str_mv AT chenxiutian signalingpathwaysofpodocyteinjuryindiabetickidneydiseaseandtheeffectofsodiumglucosecotransporter2inhibitors
AT wangjiali signalingpathwaysofpodocyteinjuryindiabetickidneydiseaseandtheeffectofsodiumglucosecotransporter2inhibitors
AT linyongda signalingpathwaysofpodocyteinjuryindiabetickidneydiseaseandtheeffectofsodiumglucosecotransporter2inhibitors
AT liuyiping signalingpathwaysofpodocyteinjuryindiabetickidneydiseaseandtheeffectofsodiumglucosecotransporter2inhibitors
AT zhoutianbiao signalingpathwaysofpodocyteinjuryindiabetickidneydiseaseandtheeffectofsodiumglucosecotransporter2inhibitors